Exelixis
EXEL
#1694
Rank
โ‚ฌ10.25 B
Marketcap
38,10ย โ‚ฌ
Share price
-0.02%
Change (1 day)
11.91%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2025 (TTM): โ‚ฌ2.04 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is โ‚ฌ1.96 Billion. In 2024 the company made a revenue of โ‚ฌ2.08 Billion an increase over the revenue in the year 2023 that were of โ‚ฌ1.65 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ2.04 B-1.66%
2024 โ‚ฌ2.08 B25.88%
2023 โ‚ฌ1.65 B10.23%
2022 โ‚ฌ1.50 B18.53%
2021 โ‚ฌ1.26 B57.82%
2020 โ‚ฌ0.80 B-7.06%
2019 โ‚ฌ0.86 B15.75%
2018 โ‚ฌ0.74 B97.91%
2017 โ‚ฌ0.37 B107.18%
2016 โ‚ฌ0.18 B435.39%
2015 โ‚ฌ33.99 M64.66%
2014 โ‚ฌ20.64 M-9.01%
2013 โ‚ฌ22.69 M-36.74%
2012 โ‚ฌ35.87 M-83.92%
2011 โ‚ฌ0.22 B60.31%
2010 โ‚ฌ0.13 B31.34%
2009 โ‚ฌ0.10 B25.64%
2008 โ‚ฌ84.3 M8.48%
2007 โ‚ฌ77.71 M3.92%
2006 โ‚ฌ74.77 M16.62%
2005 โ‚ฌ64.12 M64.56%
2004 โ‚ฌ38.96 M-4.82%
2003 โ‚ฌ40.93 M-3.45%
2002 โ‚ฌ42.39 M-8.68%
2001 โ‚ฌ46.43 M76.67%
2000 โ‚ฌ26.28 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
GlaxoSmithKline
GSK
โ‚ฌ36.37 B 1,750.91%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚ฌ40.81 B 1,976.95%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚ฌ55.17 B 2,707.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ41.25 B 1,999.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ30.89 B 1,472.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚ฌ79.14 B 3,927.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ53.92 B 2,643.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
โ‚ฌ10 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
โ‚ฌ81.01 M-95.88%๐Ÿ‡บ๐Ÿ‡ธ USA